Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041803 | 0.84 | MPO (0.53) | MPOSLC6A4TAAR1AKR1B1CA12 | |
| SCHEMBL5309632 | 0.83 | MPO (0.56) | MPOSLC6A4TAAR1AKR1B1CA12 | |
| SCHEMBL1039416 | 0.81 | MTNR1A (0.63) | MPOTSHRHIF1AKDM4EHSD17B10 | |
| SCHEMBL5647430 | 0.80 | MAPT (0.50) | TAAR1KDM4EMTNR1A | |
| SCHEMBL32665565 | 0.79 | AANAT (0.60) | MPOSLC6A4TAAR1AKR1B1CA12 | |
| SCHEMBL27586477 | 0.79 | MTNR1A (0.52) | MPOMTNR1A | |
| SCHEMBL5306684 | 0.79 | MTNR1A (0.52) | MPOSLC6A4TAAR1AKR1B1MTNR1A | |
| SCHEMBL1813320 | 0.79 | RAB9A (0.60) | MPOHIF1ASLC6A5MTNR1A | |
| SCHEMBL21358996 | 0.77 | MPO (0.50) | MPOSLC6A4MTNR1A | |
| SCHEMBL28789736 | 0.77 | MTNR1A (0.51) | MPOSLC6A4TAAR1TSHRMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | CASP3, CASP6, BAX | MPO 69/4885SLC6A4 4496/4885TAAR1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.